Zacks Investment Research on MSN1h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Dealbreaker on MSN17h
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMultiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...
22h
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback